DrugPatentWatch Database Preview

Trilaciclib dihydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for trilaciclib dihydrochloride and what is the scope of freedom to operate?

Trilaciclib dihydrochloride is the generic ingredient in one branded drug marketed by G1 Therap and is included in one NDA. There are ten patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Trilaciclib dihydrochloride has one hundred and six patent family members in twenty-five countries.

Summary for trilaciclib dihydrochloride

International Patents:	106
US Patents:	10
Tradenames:	1
Applicants:	1
NDAs:	1
Clinical Trials:	10
DailyMed Link:	trilaciclib dihydrochloride at DailyMed

Recent Clinical Trials for trilaciclib dihydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Jiangsu Simcere Pharmaceutical Co., Ltd.	Phase 4
G1 Therapeutics, Inc.	Phase 4
Jiangsu Simcere Pharmaceutical Co., Ltd.	Phase 3

See all trilaciclib dihydrochloride clinical trials

US Patents and Regulatory Information for trilaciclib dihydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
G1 Therap	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes			Y
G1 Therap	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes
G1 Therap	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes			Y
G1 Therap	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes			Y	Y
G1 Therap	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes				Y
G1 Therap	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes				Y
G1 Therap	COSELA	trilaciclib dihydrochloride	POWDER;INTRAVENOUS	214200-001	Feb 12, 2021		RX	Yes	Yes

International Patents for trilaciclib dihydrochloride

Country	Patent Number	Estimated Expiration
Japan	2016514689
Cyprus	1118004
South Korea	20190135556
European Patent Office	3118203
European Patent Office	2968291
South Korea	20140003427
Japan	2020128408